Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Taksta Stories

2013-06-13 16:26:47

CHAPEL HILL, N.C., June 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The company also intends to grant to the underwriters a 30-day option to purchase...

2013-05-30 08:29:28

Patent Protects U.S. Market Exclusivity to 2029 Excluding Possible Patent Term Extensions CHAPEL HILL, N.C., May 30, 2013 /PRNewswire/ -- Cempra, Inc., (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,450,300 on May 28, 2013 with claims directed to...

2013-05-29 16:25:57

CHAPEL HILL, N.C., May 29, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2013 Global Healthcare Conference at 1 p.m. EDT, Wednesday, June 5, at the Grand Hyatt in New York. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA(TM) (CEM-102 or fusidic acid) for the...

2013-05-28 08:21:18

- Cempra to Host Conference Call and Webcast at 8:30 a.m. EDT, Tomorrow, May 29, 2013 - CHAPEL HILL, N.C., May 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Cempra with a five year contract valued up to $58 million for the development of solithromycin to treat infections in pediatric...

2013-04-25 16:30:35

- Company to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, Apr. 25, 2013 - CHAPEL HILL, N.C., April 25, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EDT, today. "The first...

2013-04-24 16:25:59

CHAPEL HILL, N.C., April 24, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the 12(th) Annual Needham Healthcare Conference at 1:40 p.m. EDT, Wednesday, May 1, at the Westin New York Grand Central Hotel in New York. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA(TM)...

2013-02-28 16:29:04

- Company to Host Conference Call and Webcast at 4:30 p.m. EST, Today, Feb. 28, 2013 - CHAPEL HILL, N.C., Feb. 28, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2012. The company will host a conference call and webcast at 4:30...

2013-02-26 16:27:28

CHAPEL HILL, N.C., Feb. 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Cowen and Company 33(rd) Annual Health Care Conference at 2:10 p.m. EST, Monday, March 4, at the Boston Marriott Copley Place in Boston. Dr. Fernandes will provide an update of the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and...

2012-11-09 08:28:03

CHAPEL HILL, N.C., Nov. 9, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the Jefferies 2012 Global Healthcare Conference in London at 4:20 p.m. GMT, Thursday, Nov. 15, 2012, at the Waldorf Hilton in London. Dr. Fernandes will provide an update of the company's two leading antibiotic clinical programs, solithromycin (CEM-101) for community-acquired bacterial pneumonia and...

2012-11-08 16:27:58

CHAPEL HILL, N.C., Nov. 8, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the third quarter ended Sept. 30, 2012. The company will host a conference call and webcast at 4:30 p.m. EST, today. "Most of our work during the third quarter was directed toward events and activities that have...